200 related articles for article (PubMed ID: 37973340)
1. Financial incentives for reduced alcohol use and increased isoniazid adherence during tuberculosis preventive therapy among people with HIV in Uganda: an open-label, factorial randomised controlled trial.
Chamie G; Hahn JA; Kekibiina A; Emenyonu NI; Beesiga B; Marson K; Fatch R; Lodi S; Adong J; Thirumurthy H; McDonell MG; Gandhi M; Bryant K; Havlir DV; Kamya MR; Muyindike WR
Lancet Glob Health; 2023 Dec; 11(12):e1899-e1910. PubMed ID: 37973340
[TBL] [Abstract][Full Text] [Related]
2. The Drinkers' Intervention to Prevent Tuberculosis (DIPT) trial among heavy drinkers living with HIV in Uganda: study protocol of a 2×2 factorial trial.
Lodi S; Emenyonu NI; Marson K; Kwarisiima D; Fatch R; McDonell MG; Cheng DM; Thirumurthy H; Gandhi M; Camlin CS; Muyindike WR; Hahn JA; Chamie G
Trials; 2021 May; 22(1):355. PubMed ID: 34016158
[TBL] [Abstract][Full Text] [Related]
3. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
Hosseinipour MC; Bisson GP; Miyahara S; Sun X; Moses A; Riviere C; Kirui FK; Badal-Faesen S; Lagat D; Nyirenda M; Naidoo K; Hakim J; Mugyenyi P; Henostroza G; Leger PD; Lama JR; Mohapi L; Alave J; Mave V; Veloso VG; Pillay S; Kumarasamy N; Bao J; Hogg E; Jones L; Zolopa A; Kumwenda J; Gupta A;
Lancet; 2016 Mar; 387(10024):1198-209. PubMed ID: 27025337
[TBL] [Abstract][Full Text] [Related]
4. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Samandari T; Agizew TB; Nyirenda S; Tedla Z; Sibanda T; Shang N; Mosimaneotsile B; Motsamai OI; Bozeman L; Davis MK; Talbot EA; Moeti TL; Moffat HJ; Kilmarx PH; Castro KG; Wells CD
Lancet; 2011 May; 377(9777):1588-98. PubMed ID: 21492926
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Financial incentives for achieving and maintaining viral suppression among HIV-positive adults in Uganda: a randomised controlled trial.
Thirumurthy H; Ndyabakira A; Marson K; Emperador D; Kamya M; Havlir D; Kwarisiima D; Chamie G
Lancet HIV; 2019 Mar; 6(3):e155-e163. PubMed ID: 30660594
[TBL] [Abstract][Full Text] [Related]
7. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.
Rangaka MX; Wilkinson RJ; Boulle A; Glynn JR; Fielding K; van Cutsem G; Wilkinson KA; Goliath R; Mathee S; Goemaere E; Maartens G
Lancet; 2014 Aug; 384(9944):682-90. PubMed ID: 24835842
[TBL] [Abstract][Full Text] [Related]
8. A mid-level health manager intervention to promote uptake of isoniazid preventive therapy among people with HIV in Uganda: a cluster randomised trial.
Kakande E; Christian C; Balzer LB; Owaraganise A; Nugent JR; DiIeso W; Rast D; Kabami J; Johnson Peretz J; Camlin CS; Shade SB; Geng EH; Kwarisiima D; Kamya MR; Havlir DV; Chamie G
Lancet HIV; 2022 Sep; 9(9):e607-e616. PubMed ID: 35908553
[TBL] [Abstract][Full Text] [Related]
9. Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda.
Barnabas RV; van Rooyen H; Tumwesigye E; Brantley J; Baeten JM; van Heerden A; Turyamureeba B; Joseph P; Krows M; Thomas KK; Schaafsma TT; Hughes JP; Celum C
Lancet HIV; 2016 May; 3(5):e212-20. PubMed ID: 27126488
[TBL] [Abstract][Full Text] [Related]
10. Financial incentives to promote retention in care and viral suppression in adults with HIV initiating antiretroviral therapy in Tanzania: a three-arm randomised controlled trial.
Fahey CA; Njau PF; Katabaro E; Mfaume RS; Ulenga N; Mwenda N; Bradshaw PT; Dow WH; Padian NS; Jewell NP; McCoy SI
Lancet HIV; 2020 Nov; 7(11):e762-e771. PubMed ID: 32891234
[TBL] [Abstract][Full Text] [Related]
11. Unhealthy Alcohol Use Is Associated With Suboptimal Adherence to Isoniazid Preventive Therapy in Persons With HIV in Southwestern Uganda.
Muyindike WR; Fatch R; Cheng DM; Emenyonu NI; Forman L; Ngabirano C; Adong J; Linas B; Jacobson KR; Hahn JA
J Acquir Immune Defic Syndr; 2022 Dec; 91(5):460-468. PubMed ID: 36044285
[TBL] [Abstract][Full Text] [Related]
12. Association between smoking and lack of HIV virological suppression in a cross-sectional study of persons with HIV on antiretroviral therapy in Uganda.
Tumwegamire A; Fatch R; Emenyonu NI; Lodi S; Muyindike WR; Kekibiina A; Adong J; Ngabirano C; Beesiga B; Marson K; Golabi N; Kamya M; Chamie G; Hahn JA
PLoS One; 2024; 19(3):e0300508. PubMed ID: 38507431
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of a digital medication event reminder and monitor device for patients with tuberculosis (SELFTB): a multicenter randomized controlled trial.
Manyazewal T; Woldeamanuel Y; Holland DP; Fekadu A; Marconi VC
BMC Med; 2022 Sep; 20(1):310. PubMed ID: 36167528
[TBL] [Abstract][Full Text] [Related]
14. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
[TBL] [Abstract][Full Text] [Related]
15. Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial.
Gupta A; Singh P; Aaron L; Montepiedra G; Chipato T; Stranix-Chibanda L; Chanaiwa V; Vhembo T; Mutambanengwe M; Masheto G; Raesi M; Bradford S; Golner A; Costello D; Kulkarni V; Shayo A; Kabugho E; Jean-Phillippe P; Chakhtoura N; Sterling TR; Theron G; Weinberg A;
Lancet Child Adolesc Health; 2023 Oct; 7(10):708-717. PubMed ID: 37634517
[TBL] [Abstract][Full Text] [Related]
16. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
Ndiaye BP; Thienemann F; Ota M; Landry BS; Camara M; Dièye S; Dieye TN; Esmail H; Goliath R; Huygen K; January V; Ndiaye I; Oni T; Raine M; Romano M; Satti I; Sutton S; Thiam A; Wilkinson KA; Mboup S; Wilkinson RJ; McShane H;
Lancet Respir Med; 2015 Mar; 3(3):190-200. PubMed ID: 25726088
[TBL] [Abstract][Full Text] [Related]
17. Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania.
Hunter OF; Kyesi F; Ahluwalia AK; Daffé ZN; Munseri P; von Reyn CF; Adams LV
BMC Infect Dis; 2020 Oct; 20(1):738. PubMed ID: 33028260
[TBL] [Abstract][Full Text] [Related]
18. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.
Dooley KE; Savic R; Gupte A; Marzinke MA; Zhang N; Edward VA; Wolf L; Sebe M; Likoti M; Fyvie MJ; Shibambo I; Beattie T; Chaisson RE; Churchyard GJ;
Lancet HIV; 2020 Jun; 7(6):e401-e409. PubMed ID: 32240629
[TBL] [Abstract][Full Text] [Related]
19. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.
Scriba TJ; Fiore-Gartland A; Penn-Nicholson A; Mulenga H; Kimbung Mbandi S; Borate B; Mendelsohn SC; Hadley K; Hikuam C; Kaskar M; Musvosvi M; Bilek N; Self S; Sumner T; White RG; Erasmus M; Jaxa L; Raphela R; Innes C; Brumskine W; Hiemstra A; Malherbe ST; Hassan-Moosa R; Tameris M; Walzl G; Naidoo K; Churchyard G; Hatherill M;
Lancet Infect Dis; 2021 Mar; 21(3):354-365. PubMed ID: 33508224
[TBL] [Abstract][Full Text] [Related]
20. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Durovni B; Saraceni V; Moulton LH; Pacheco AG; Cavalcante SC; King BS; Cohn S; Efron A; Chaisson RE; Golub JE
Lancet Infect Dis; 2013 Oct; 13(10):852-8. PubMed ID: 23954450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
